ADAM17 promotes motility, invasion, and sprouting of lymphatic endothelial cells

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Męzyk Kopeć, Renata ^a,b,c   Wyroba, Barbara ^a   Stalińska, Krystyna ^a   Próchnicki, Tomasz ^a,d   Wiatrowska, Karolina ^a   Kilarski, Witold W ^b,c   Swartz, Melody A ^b,c   Bereta, Joanna ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b EPFL   (Switzerland)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; ARGINYLGLYCYLASPARTIC ACID; COLLAGEN TYPE 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; INTEGRIN; PEPTIDES AND PROTEINS; PROTEIN ADAM17; PROTEIN BIG H3; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; ADAM PROTEIN; ADAM17 PROTEIN, HUMAN; BETAIG-H3 PROTEIN; CELL SURFACE RECEPTOR; CULTURE MEDIUM; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ARTICLE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE SILENCING; HUMAN; HUMAN CELL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; CELL LINE; CELL MOTION; CELL SURVIVAL; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECTS; METABOLISM;

ADAM PROTEINS; ADAM17 PROTEIN; CELL ADHESION; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; GENE SILENCING; HUMANS; INTEGRINS; LYMPHANGIOGENESIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

EID: 84941339939     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132661     Document Type: Article

References (66)

1. Karaman S, Detmar M. Mechanisms of lymphatic metastasis. J Clin Invest. 2014; 124(3):922-8. Epub 2014/03/05. doi: 10.1172/JCI71606 PMID: 24590277; PubMed Central PMCID: PMC3938272.
2. Das S, Sarrou E, Podgrabinska S, Cassella M, Mungamuri SK, Feirt N, et al. Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. J Exp Med. 2013; 210(8):1509-28. Epub 2013/07/24. doi: 10.1084/jem.20111627 PMID: 23878309; PubMed Central PMCID: PMC3727324.
3. Miteva DO, Rutkowski JM, Dixon JB, Kilarski W, Shields JD, Swartz MA. Transmural flow modulates cell and fluid transport functions of lymphatic endothelium. Circ Res. 2010; 106(5):920-31. Epub 2010/02/06. doi: 10.1161/CIRCRESAHA.109.207274 PMID: 20133901.
4. Wick N, Haluza D, Gurnhofer E, Raab I, Kasimir MT, Prinz M, et al. Lymphatic precollectors contain a novel, specialized subpopulation of podoplanin low, CCL27-expressing lymphatic endothelial cells. Am J Pathol. 2008; 173(4):1202-9. Epub 2008/09/06. doi: 10.2353/ajpath.2008.080101 PMID: 18772332; PubMed Central PMCID: PMC2543086.
5. Christiansen A, Detmar M. Lymphangiogenesis and cancer. Genes Cancer. 2011; 2(12):1146-58. Epub 2012/08/07. doi: 10.1177/1947601911423028 PMID: 22866206; PubMed Central PMCID: PMC3411123.
6. Hirosue S, Vokali E, Raghavan VR, Rincon-Restrepo M, Lund AW, Corthesy-Henrioud P, et al. Steadystate antigen scavenging, cross-presentation, and CD8+ T cell priming: a new role for lymphatic endothelial cells. J Immunol. 2014; 192(11):5002-11. Epub 2014/05/06. doi: 10.4049/jimmunol.1302492 PMID: 24795456; PubMed Central PMCID: PMC4025611.
7. Tewalt EF, Cohen JN, Rouhani SJ, Engelhard VH. Lymphatic endothelial cells-key players in regulation of tolerance and immunity. Front Immunol. 2012; 3:305. Epub 2012/10/13. doi: 10.3389/fimmu. 2012.00305 PMID: 23060883; PubMed Central PMCID: PMC3460259.
8. Wang Y, Oliver G. Current views on the function of the lymphatic vasculature in health and disease. Genes Dev. 2010; 24(19):2115-26. Epub 2010/10/05. doi: 10.1101/gad.1955910 PMID: 20889712; PubMed Central PMCID: PMC2947764.
9. Goldman J, Rutkowski JM, Shields JD, Pasquier MC, Cui Y, Schmokel HG, et al. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. Faseb J. 2007; 21 (4):1003-12. Epub 2007/01/11. doi: 10.1096/fj.06-6656com PMID: 17210781.
10. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Molecular aspects of medicine. 2008; 29(5):258-89. Epub 2008/09/03. doi: 10.1016/j.mam.2008.08.001 PMID: 18762209.
11. Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends in immunology. 2011; 32(8):380-7. Epub 2011/07/15. doi: 10.1016/j.it. 2011.05.005 PMID: 21752713.
12. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nature reviews Cancer. 2008; 8(12):929-41. Epub 2008/11/14. doi: 10.1038/nrc2459 PMID: 19005493.
13. Das S, Czarnek M, Bzowska M, Mezyk-Kopec R, Stalinska K, Wyroba B, et al. ADAM17 silencing in mouse colon carcinoma cells: the effect on tumoricidal cytokines and angiogenesis. PLoS One. 2012; 7 (12):e50791. Epub 2012/12/20. doi: 10.1371/journal.pone.0050791 PMID: 23251384; PubMed Central PMCID: PMC3519469.
14. Franovic A, Robert I, Smith K, Kurban G, Pause A, Gunaratnam L, et al. Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Cancer research. 2006; 66(16):8083-90. Epub 2006/08/17. doi: 10.1158/0008-5472.CAN-06-1595 PMID: 16912185.
15. Kenny PA, Bissell MJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest. 2007; 117(2):337-45. Epub 2007/01/16. doi: 10.1172/JCI29518 PMID: 17218988; PubMed Central PMCID: PMC1764856.
16. McGowan PM, Ryan BM, Hill AD, McDermott E, O'Higgins N, Duffy MJ. ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13(8):2335-43. Epub 2007/04/18. doi: 10.1158/1078-0432.CCR-06-2092 PMID: 17438092.
17. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol. 2005; 6(1):32-43. Epub 2005/02/03. doi: 10.1038/nrm1548 PMID: 15688065.
18. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007; 98 (5):621-8. Epub 2007/03/16. doi: 10.1111/j.1349-7006.2007.00434.x PMID: 17355265.
19. Gooz P, Gooz M, Baldys A, Hoffman S. ADAM-17 regulates endothelial cell morphology, proliferation, and in vitro angiogenesis. Biochem Biophys Res Commun. 2009; 380(1):33-8. Epub 2009/01/20. doi: 10.1016/j.bbrc.2009.01.013 PMID: 19150341; PubMed Central PMCID: PMC2875258.
20. Zheng X, Jiang F, Katakowski M, Lu Y, Chopp M. ADAM17 promotes glioma cell malignant phenotype. Mol Carcinog. 2012; 51(2):150-64. Epub 2011/04/12. doi: 10.1002/mc.20772 PMID: 21480393; PubMed Central PMCID: PMC3234333.
21. Maretzky T, Evers A, Zhou W, Swendeman SL, Wong PM, Rafii S, et al. Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. Nature communications. 2011; 2:229. Epub 2011/03/17. doi: 10.1038/ncomms1232 PMID: 21407195; PubMed Central PMCID: PMC3074487.
22. McGowan PM, Mullooly M, Caiazza F, Sukor S, Madden SF, Maguire AA, et al. ADAM-17: a novel therapeutic target for triple negative breast cancer. Ann Oncol. 2013; 24(2):362-9. Epub 2012/09/13. doi: 10.1093/annonc/mds279 PMID: 22967992.
23. Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des. 2009; 15 (20):2319-35. Epub 2009/07/16. PMID: 19601834.
24. Weskamp G, Mendelson K, Swendeman S, Le Gall S, Ma Y, Lyman S, et al. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ Res. 2010; 106(5):932-40. Epub 2010/01/30. doi: 10.1161/CIRCRESAHA.109.207415 PMID: 20110534; PubMed Central PMCID: PMC2842448.
25. Yang J, Chang E, Cherry AM, Bangs CD, Oei Y, Bodnar A, et al. Human endothelial cell life extension by telomerase expression. J Biol Chem. 1999; 274(37):26141-8. Epub 1999/09/03. PMID: 10473565.
26. Yang J, Nagavarapu U, Relloma K, Sjaastad MD, Moss WC, Passaniti A, et al. Telomerized human microvasculature is functional in vivo. Nat Biotechnol. 2001; 19(3):219-24. Epub 2001/03/07. doi: 10.1038/85655 PMID: 11231553.
27. Schoppmann SF, Soleiman A, Kalt R, Okubo Y, Benisch C, Nagavarapu U, et al. Telomerase-immortalized lymphatic and blood vessel endothelial cells are functionally stable and retain their lineage specificity. Microcirculation. 2004; 11(3):261-9. Epub 2004/07/29. doi: 10.1080/10739680490425967 PMID: 15280080.
28. Coligan J, Dunn B, Ploegh H, Speicher D, Wingfield P, editors. Current Protocols in Protein Science,. New York: John Wiley & Sons; 1997.
29. Celis J, editor. Cell Biology: A Laboratory Handbook. London: Academic Press; 1998.
30. Sroka J, Antosik A, Czyz J, Nalvarte I, Olsson JM, Spyrou G, et al. Overexpression of thioredoxin reductase 1 inhibits migration of HEK-293 cells. Biology of the cell/under the auspices of the European Cell Biology Organization. 2007; 99(12):677-87. Epub 2007/06/22. doi: 10.1042/BC20070024 PMID: 17581112.
31. Korff T, Augustin HG. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol. 1998; 143(5):1341-52. Epub 1998/12/02. PMID: 9832561; PubMed Central PMCID: PMC2133072.
32. Huttenlocher A, Horwitz AR. Integrins in cell migration. Cold Spring Harb Perspect Biol. 2011; 3(9): a005074. Epub 2011/09/03. doi: 10.1101/cshperspect.a005074 PMID: 21885598; PubMed Central PMCID: PMC3181029.
33. Blacher S, Erpicum C, Lenoir B, Paupert J, Moraes G, Ormenese S, et al. Cell invasion in the spheroid sprouting assay: a spatial organisation analysis adaptable to cell behaviour. PLoS One. 2014; 9(5): e97019. Epub 2014/05/09. doi: 10.1371/journal.pone.0097019 PMID: 24806521; PubMed Central PMCID: PMC4013117.
34. Chen J, Alexander JS, Orr AW. Integrins and their extracellular matrix ligands in lymphangiogenesis and lymph node metastasis. Int J Cell Biol. 2012; 2012:853703. Epub 2012/04/17. doi: 10.1155/2012/853703 PMID: 22505936; PubMed Central PMCID: PMC3296286.
35. Yoda M, Kimura T, Tohmonda T, Morioka H, Matsumoto M, Okada Y, et al. Systemic overexpression of TNFalpha-converting enzyme does not lead to enhanced shedding activity in vivo. PLoS One. 2013; 8 (1):e54412. Epub 2013/01/24. doi: 10.1371/journal.pone.0054412 PMID: 23342154; PubMed Central PMCID: PMC3544834.
36. Fukaya S, Matsui Y, Tomaru U, Kawakami A, Sogo S, Bohgaki T, et al. Overexpression of TNF-alphaconverting enzyme in fibroblasts augments dermal fibrosis after inflammation. Lab Invest. 2013; 93 (1):72-80. Epub 2012/11/14. doi: 10.1038/labinvest.2012.153 PMID: 23147225.
37. Bell JH, Herrera AH, Li Y, Walcheck B. Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by neutrophils and macrophages. J Leukoc Biol. 2007; 82(1):173-6. Epub 2007/05/19. doi: 10.1189/jlb.0307193 PMID: 17510296.
38. Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, Schirmacher P, et al. Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med. 2010; 207(8):1617-24. Epub 2010/07/07. doi: 10.1084/jem.20092366 PMID: 20603312; PubMed Central PMCID: PMC2916135.
39. Dreymueller D, Martin C, Kogel T, Pruessmeyer J, Hess FM, Horiuchi K, et al. Lung endothelial ADAM17 regulates the acute inflammatory response to lipopolysaccharide. EMBO Mol Med. 2012; 4 (5):412-23. Epub 2012/03/01. doi: 10.1002/emmm.201200217 PMID: 22367719; PubMed Central PMCID: PMC3403298.
40. Gschwind A, Hart S, Fischer OM, Ullrich A. TACE cleavage of proamphiregulin regulates GPCRinduced proliferation and motility of cancer cells. Embo J. 2003; 22(10):2411-21. PMID: 12743035.
41. Bax DV, Messent AJ, Tart J, van Hoang M, Kott J, Maciewicz RA, et al. Integrin alpha5beta1 and ADAM-17 interact in vitro and co-localize in migrating HeLa cells. J Biol Chem. 2004; 279(21):22377-86. Epub 2004/02/19. doi: 10.1074/jbc.M400180200 PMID: 14970227.
42. Eliceiri BP. Integrin and growth factor receptor crosstalk. Circ Res. 2001; 89(12):1104-10. Epub 2001/12/12. PMID: 11739274.
43. Goitre L, Pergolizzi B, Ferro E, Trabalzini L, Retta SF. Molecular Crosstalk between Integrins and Cadherins: Do Reactive Oxygen Species Set the Talk? J Signal Transduct. 2012; 2012:807682. Epub 2011/12/29. doi: 10.1155/2012/807682 PMID: 22203898; PubMed Central PMCID: PMC3238397.
44. Morgan MR, Hamidi H, Bass MD, Warwood S, Ballestrem C, Humphries MJ. Syndecan-4 phosphorylation is a control point for integrin recycling. Dev Cell. 2013; 24(5):472-85. Epub 2013/03/05. doi: 10.1016/j.devcel.2013.01.027 PMID: 23453597; PubMed Central PMCID: PMC3605578.
45. Fedak PW, Moravec CS, McCarthy PM, Altamentova SM, Wong AP, Skrtic M, et al. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation. 2006; 113(2):238-45. Epub 2006/01/13. doi: 10.1161/CIRCULATIONAHA.105.571414 PMID: 16401770.
46. Tsubota Y, Frey JM, Tai PW, Welikson RE, Raines EW. Monocyte ADAM17 promotes diapedesis during transendothelial migration: identification of steps and substrates targeted by metalloproteinases. Journal of immunology. 2013; 190(8):4236-44. Epub 2013/03/13. doi: 10.4049/jimmunol.1300046 PMID: 23479224; PubMed Central PMCID: PMC3622190.
47. Klamer SE, Kuijk CG, Hordijk PL, van der Schoot CE, von Lindern M, van Hennik PB, et al. BIGH3 modulates adhesion and migration of hematopoietic stem and progenitor cells. Cell Adh Migr. 2013; 7 (5):434-49. Epub 2013/10/25. doi: 10.4161/cam.26596 PMID: 24152593; PubMed Central PMCID: PMC3903689.
48. Nam EJ, Sa KH, You DW, Cho JH, Seo JS, Han SW, et al. Up-regulated transforming growth factor beta-inducible gene h3 in rheumatoid arthritis mediates adhesion and migration of synoviocytes through alpha v beta3 integrin: Regulation by cytokines. Arthritis Rheum. 2006; 54(9):2734-44. Epub 2006/09/02. doi: 10.1002/art.22076 PMID: 16947382.
49. Tumbarello DA, Temple J, Brenton JD. ss3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells. Mol Cancer. 2012; 11:36. Epub 2012/05/30. doi: 10.1186/1476-4598-11-36 PMID: 22640878; PubMed Central PMCID: PMC3442987.
50. Zhang Y, Wen G, Shao G, Wang C, Lin C, Fang H, et al. TGFBI deficiency predisposes mice to spontaneous tumor development. Cancer research. 2009; 69(1):37-44. Epub 2009/01/02. doi: 10.1158/0008-5472.CAN-08-1648 PMID: 19117985; PubMed Central PMCID: PMC2664305.
51. Irigoyen M, Anso E, Salvo E, Dotor de las Herrerias J, Martinez-Irujo JJ, Rouzaut A. TGFbeta-induced protein mediates lymphatic endothelial cell adhesion to the extracellular matrix under low oxygen conditions. Cell Mol Life Sci. 2008; 65(14):2244-55. Epub 2008/06/19. doi: 10.1007/s00018-008-8071-9 PMID: 18560760.
52. Nees M, Geoghegan JM, Munson P, Prabhu V, Liu Y, Androphy E, et al. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. Cancer research. 2000; 60(15):4289-98. Epub 2000/08/17. PMID: 10945644.
53. Lee NY, Ray B, How T, Blobe GC. Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J Biol Chem. 2008; 283(47):32527-33. Epub 2008/09/09. doi: 10.1074/jbc.M803059200 PMID: 18775991; PubMed Central PMCID: PMC2583306.
54. James JM, Nalbandian A, Mukouyama YS. TGFbeta signaling is required for sprouting lymphangiogenesis during lymphatic network development in the skin. Development. 2013; 140(18):3903-14. Epub 2013/08/16. doi: 10.1242/dev.095026 PMID: 23946447; PubMed Central PMCID: PMC3754483.
55. Avraham T, Clavin NW, Daluvoy SV, Fernandez J, Soares MA, Cordeiro AP, et al. Fibrosis is a key inhibitor of lymphatic regeneration. Plast Reconstr Surg. 2009; 124(2):438-50. Epub 2009/08/01. doi: 10.1097/PRS.0b013e3181adcf4b PMID: 19644258.
56. Avraham T, Daluvoy S, Zampell J, Yan A, Haviv YS, Rockson SG, et al. Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair. Am J Pathol. 2010; 177 (6):3202-14. Epub 2010/11/09. doi: 10.2353/ajpath.2010.100594 PMID: 21056998; PubMed Central PMCID: PMC2993295.
57. Clavin NW, Avraham T, Fernandez J, Daluvoy SV, Soares MA, Chaudhry A, et al. TGF-beta1 is a negative regulator of lymphatic regeneration during wound repair. Am J Physiol Heart Circ Physiol. 2008; 295(5):H2113-27. Epub 2008/10/14. doi: 10.1152/ajpheart.00879.2008 PMID: 18849330.
58. Oka M, Iwata C, Suzuki HI, Kiyono K, Morishita Y, Watabe T, et al. Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood. 2008; 111(9):4571-9. Epub 2008/03/04. doi: 10.1182/blood-2007-10-120337 PMID: 18310502.
59. Yan A, Avraham T, Zampell JC, Haviv YS, Weitman E, Mehrara BJ. Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-beta1 inhibition. Future Oncol. 2011; 7(12):1457-73. Epub 2011/11/25. doi: 10.2217/fon.11.121 PMID: 22112321; PubMed Central PMCID: PMC3263831.
60. Liu C, Xu P, Lamouille S, Xu J, Derynck R. TACE-mediated ectodomain shedding of the type I TGFbeta receptor downregulates TGF-beta signaling. Mol Cell. 2009; 35(1):26-36. Epub 2009/07/15. doi: 10.1016/j.molcel.2009.06.018 PMID: 19595713; PubMed Central PMCID: PMC2740991.
61. Malapeira J, Esselens C, Bech-Serra JJ, Canals F, Arribas J. ADAM17 (TACE) regulates TGFbeta signaling through the cleavage of vasorin. Oncogene. 2011; 30(16):1912-22. Epub 2010/12/21. doi: 10.1038/onc.2010.565 PMID: 21170088.
62. Ebi M, Kataoka H, Shimura T, Kubota E, Hirata Y, Mizushima T, et al. TGFbeta induces proHB-EGF shedding and EGFR transactivation through ADAM activation in gastric cancer cells. Biochem Biophys Res Commun. 2010; 402(3):449-54. Epub 2010/10/12. doi: 10.1016/j.bbrc.2010.09.130 PMID: 20934403.
63. Uchiyama-Tanaka Y, Matsubara H, Mori Y, Kosaki A, Kishimoto N, Amano K, et al. Involvement of HBEGF and EGF receptor transactivation in TGF-beta-mediated fibronectin expression in mesangial cells. Kidney Int. 2002; 62(3):799-808. Epub 2002/08/08. doi: 10.1046/j.1523-1755.2002.00537.x PMID: 12164862.
64. Moreno-Caceres J, Caja L, Mainez J, Mayoral R, Martin-Sanz P, Moreno-Vicente R, et al. Caveolin-1 is required for TGF-beta-induced transactivation of the EGF receptor pathway in hepatocytes through the activation of the metalloprotease TACE/ADAM17. Cell Death Dis. 2014; 5:e1326. Epub 2014/07/18. doi: 10.1038/cddis.2014.294 PMID: 25032849.
65. Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, Pierce A, et al. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clinical proteomics. 2011; 8(1):9. Epub 2011/09/13. doi: 10.1186/1559-0275-8-9 PMID: 21906355; PubMed Central PMCID: PMC3170276.
66. Tape CJ, Willems SH, Dombernowsky SL, Stanley PL, Fogarasi M, Ouwehand W, et al. Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci U S A. 2011; 108(14):5578-83. Epub 2011/03/19. doi: 10.1073/pnas.1017067108 PMID: 21415364; PubMed Central PMCID: PMC3078358.